Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy – a single-centre experience
Open Access
- 2 February 2016
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 11 (1) , 12
Abstract
To assess efficacy of our single-centre experience with inhalative steroids (IS) in lung cancer patients with symptomatic radiation pneumonitis (RP) grade II. Between 05/09 and 07/10, 24 patients (female, n = 8; male, n = 16) with lung cancer (non-small cell lung carcinoma [NSCLC]: n = 19; small cell lung cancer [SCLC]: n = 3; unknown histology: n = 2) and good performance status (ECOG ≤1) received definitive radiotherapy to the primary tumour site and involved lymph nodes with concurrent chemotherapy (n = 18), sequential chemotherapy (n = 2) or radiation only (n = 4) and developed symptomatic RP grade II during follow-up. No patient presented with oxygen requiring RP grade III. The mean age at diagnosis was 66 years (range: 50–82 years). Nine patients suffered from chronic obstructive pulmonary disease (COPD) before treatment, and 18 patients had a smoking history (median pack years: 48). The mean lung dose was 15.5 Gy (range: 3.0–23.1 Gy). All patients were treated with IS. If a patient’s clinical symptoms did not significantly improve within two weeks of IS therapy initiation, their treatment was switched to oral prednisolone. All 24 patients were initially treated with a high dose IS (budesonide 800 μg 1-0-1) for 14 days. Of the patients, 18 showed a significant improvement of clinical symptoms and 6 patients did not show significant improvement of clinical symptoms and were classified as non-responders to IS. Their treatment was switched to oral steroids after two weeks (starting with oral prednisolone, 0.5 mg/kg bodyweight; at least 50 mg per day). All of these patients responded to the prednisolone. None of non-responders presented with increased symptoms of RP and required oxygen and / or hospitalization (RP grade III). The median follow-up after IS treatment initiation was 18 months (range: 4–66 months). The median duration of IS treatment and prednisolone treatment was 8.2 months (range: 3.0–48.3 months) and 11.4 months (range: 5.0–44.0 months), respectively. Of the 18 IS treatment responders, 2 (11.1 %) patients with pre-existing grade 2 COPD still required IS (400 μg twice a day) 45.0 and 48.3 months after radiotherapy, respectively. For the remaining 16 responders (88.9 %), IS therapy was stopped after 7.7 months (range: 3.0–18.2 months). None of the patients treated with IS developed any specific IS-related side effects such as oral candidiasis. This single-centre experience shows that high-dose IS is an individual treatment option for radiation-induced pneumonitis grade II in patients with a good performance status.Keywords
This publication has 36 references indexed in Scilit:
- Impact of 3D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer: A Prospective StudyRespiration, 2012
- Prediction of radiation pneumonitis in lung cancer patients: a systematic reviewJournal of Cancer Research and Clinical Oncology, 2012
- COPD exacerbations in general practice: variability in oral prednisolone coursesBMC Family Practice, 2012
- Increased Systemic Cortisol Metabolism in Patients With Schizophrenia and Bipolar DisorderThe Journal of Clinical Psychiatry, 2011
- Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapyJournal of Cancer Research and Clinical Oncology, 2010
- The Impact of Induction Chemotherapy and the Associated Tumor Response on Subsequent Radiation-Related Changes in Lung Function and Tumor ResponseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patientsRadiotherapy and Oncology, 2006
- Inhalative versus systemische Pneumonitisprophylaxe bei ThoraxbestrahlungenStrahlentherapie und Onkologie, 1998
- Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991
- Does Smoking Protect Against Radiation-induced Pneumonitis?International Journal of Radiation Biology, 1989